We have reached an inflection point in efforts to improve patients' access to innovative medicines. In recent years, we have seen significant advancements in treatments for ALS, cancer, and HIV that have increased lifespan, slowed disease progression, and improved quality of life for millions of patients. Meanwhile, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law - legislation that seeks to help American families afford everyday necessities and includes provision intended to lower prescription drug costs. As the Centers for Medicare & Medicaid Services (CMS) moves to implement these largescale policies, the agency must ensure that it creates meaningful opportunities for patient and other stakeholder communities to participate in the regulatory process. In doing so, CMS will ensure patients most impacted by the law and most familiar with the direct impacts of such policies are heard.
Read Full Article »
